Skip to main content
SpringerLink
Log in

Health-Related Quality of Life Related to Toxicity Treatments in Central Nervous System Metastases

  • Chapter
  • First Online:
Central Nervous System Metastases

Abstract

Health-related quality of life (HRQoL) is a multidimensional concept that measures how a disease and the treatment of that disease impact a patient’s life. It can also aid in the dialogue between physician and patient. As different therapies have distinct mechanisms, the HRQoL of a patient might be affected in diverse ways depending on the particular side effects that he or she experiences. This chapter discusses the importance of HRQoL related to treatment toxicity, the different tools that are used to measure this outcome, and how different therapeutic modalities impact the patient with central nervous system (CNS) metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Meyers CA, Rock EP, Fine HA. Refining endpoints in brain tumor clinical trials. J Neuro-Oncol. 2012;108(2):227–30. https://doi.org/10.1007/s11060-012-0813-8.

    Article  Google Scholar 

  2. Habets EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, Lycklama ANGJ, Zwinkels H, Klein M, Taphoorn MJ. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-Oncology. 2016;18(3):435–44. https://doi.org/10.1093/neuonc/nov186.

    Article  CAS  PubMed  Google Scholar 

  3. Castrucci WA, Knisely JP. An update on the treatment of CNS metastases in small cell lung cancer. Cancer J. 2008;14(3):138–46. https://doi.org/10.1097/PPO.0b013e318172d6e1.

    Article  PubMed  Google Scholar 

  4. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–62. https://doi.org/10.1016/j.ctrv.2016.03.009.

    Article  PubMed  Google Scholar 

  5. Lu-Emerson C, Eichler AF. Brain Metastasis. Continuum. 2012;18(2):295–311.

    PubMed  Google Scholar 

  6. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. Neuro-Oncology. 2016;18(8):1043–65. https://doi.org/10.1093/neuonc/now127.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the jumpstarting brain tumor drug development coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro-Oncology. 2016;18(suppl 2):ii26–36. https://doi.org/10.1093/neuonc/nov270.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Walbert T, Mendoza TR, Vera-Bolanos E, Acquaye A, Gilbert MR, Armstrong TS. Symptoms and socio-economic impact of ependymoma on adult patients: results of the adult Ependymoma outcomes project 2. J Neuro-Oncol. 2015;121(2):341–8. https://doi.org/10.1007/s11060-014-1638-4.

    Article  Google Scholar 

  9. Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States. J Med Econ. 2017;20(1):54–62. https://doi.org/10.1080/13696998.2016.1225577.

    Article  PubMed  Google Scholar 

  10. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: CM M, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191 e205.

    Google Scholar 

  11. Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E. Quality of life in brain metastasis radiation trials : a literature review. Curr Oncol Rep. 2008;15(5):25–45.

    CAS  Google Scholar 

  12. Hutchison TA, Boyd NF, Feinstein AR. Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis. 1979;32(661):e6.

    Google Scholar 

  13. Witgert ME, Meyers CA. Neurocognitive and quality of life measures in patients with metastatic brain disease. Neurosurg Clin N Am. 2011;22:79–85.

    Article  PubMed  Google Scholar 

  14. Kepka LT-SD, Osowiecka K, Sprawka A, Trąbska-Kluch B, Czeremszynska B. Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial. Clin Transl Oncol. 2018;20(2):150–9. https://doi.org/10.1007/s12094-017-1703-5.

    Article  CAS  PubMed  Google Scholar 

  15. Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-Oncology. 2016;18(Suppl 2):ii13–20. https://doi.org/10.1093/neuonc/nov291.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff RO, van den Bent MJ, Bottomley A, Group EQoL, Brain Cancer N, Radiotherapy G. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033–40. https://doi.org/10.1016/j.ejca.2010.01.012.

    Article  PubMed  Google Scholar 

  17. Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ, Dutch Neuro-Oncology G. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer. 2015;51(10):1321–30. https://doi.org/10.1016/j.ejca.2015.03.025.

    Article  CAS  PubMed  Google Scholar 

  18. Osoba D, Aarson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139–50.

    Article  CAS  PubMed  Google Scholar 

  19. Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, Cleeland CS. Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manag. 2009;37(3):331–40. https://doi.org/10.1016/j.jpainsymman.2008.02.011.

    Article  Google Scholar 

  20. Armstrong TS, Mendoza T, Gning I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C. Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). J Neuro-Oncol. 2006;80(1):27–35. https://doi.org/10.1007/s11060-006-9135-z.

    Article  CAS  Google Scholar 

  21. Armstrong TS, Vera-Bolanos E, Acquaye A, Gilbert MR, Mendoza TR. Impact of recall period on primary brain tumor patient's self-report of symptoms. Neurooncol Pract. 2014;1(2):55–63. https://doi.org/10.1093/nop/npu006.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lai JSJS, Beaumont JL, Abernethy AP, Jacobsen PB, Syrjala K, Raizer JJ, Cella D. Development of a symptom index for patients with primary brain tumors. Value Health. 2014;17(1):62–9. https://doi.org/10.1016/j.jval.2013.11.006.

    Article  PubMed  Google Scholar 

  23. Jakola AS, Gulati M, Gulati S, Solheim O. The influence of surgery on quality of life in patients with intracranial meningiomas: a prospective study. J Neuro-Oncol. 2012;110(1):137–44. https://doi.org/10.1007/s11060-012-0947-8.

    Article  Google Scholar 

  24. Jakola AS, Gulati S, Weber C, Unsgard G, Solheim O. Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One. 2011;6(12):e28592. https://doi.org/10.1371/journal.pone.0028592.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Miller JAKR, Barnett GH, Suh JH, Angelov L, Murphy ES, Vogelbaum MA, Mohammadi A, Chao ST. Quality of life following stereotactic radiosurgery for single and multiple brain metastases. Neurosurgery. 2017;81(1):147–55. https://doi.org/10.1093/neuros/nyw166.

    Article  PubMed  Google Scholar 

  26. Kanner AA, Bokstein F, Blumenthal DT, Ram Z. Surgical therapies in brain metastasis. Semin Oncol. 2007;34(3):197–205. https://doi.org/10.1053/j.seminoncol.2007.03.011.

    Article  PubMed  Google Scholar 

  27. Raco A, Pesce A, Fraschetti F, D'Andrea G, Polli FM, Acqui M, Frati A. Risk of postoperative performance status worsening after resection of lesions involving the motor pathway: a multinomial logistic regression model. J Neurol Surg A Cent Eur Neurosurg. 2018; https://doi.org/10.1055/s-0037-1617756.

    Article  Google Scholar 

  28. Tsao MNRD, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210–25.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Andrews DWSC, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.

    Article  PubMed  Google Scholar 

  30. Bragstad S, Flatebo M, Natvig GK, Eide GE, Skeie GO, Behbahani M, Pedersen PH, Enger PO, Skeie BS. Predictors of quality of life and survival following gamma knife surgery for lung cancer brain metastases: a prospective study. J Neurosurg. 2018;129(1):71–83. https://doi.org/10.3171/2017.2.JNS161659.

    Article  PubMed  Google Scholar 

  31. Steinmann D, Paelecke-Habermann Y, Geinitz H, Aschoff R, Bayerl A, Bolling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Muller A, Schafer C, Schleicher U, Sehlen S, Theodorou M, Wypior HJ, Zehentmayr F, van Oorschot B, Vordermark D. Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer. 2012;12(283):283. https://doi.org/10.1186/1471-2407-12-283.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wong E, Rowbottom L, Tsao M, Zhang L, McDonald R, Danjoux C, Barnes E, Chan S, Chow E. Prognostic value of pre- and post-treatment health-related quality of life in predicting survival of patients with brain metastases. CNS Oncol. 2017;6(2):119–29. https://doi.org/10.2217/cns-2016-0020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Edelstein K, Richard NM, Bernstein LJ. Neurocognitive impact of cranial radiation in adults with cancer: an update of recent findings. Curr Opin Support Palliat Care. 2017;11(1):32–7. https://doi.org/10.1097/SPC.0000000000000255.

    Article  PubMed  Google Scholar 

  34. Pruit AA. Epidemiology, treatment, and complications of central nervous metastases. Continuum Neuro Oncol. 2017;23(6):1580–600.

    Google Scholar 

  35. Armstrong TSCS, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707–15. https://doi.org/10.1002/cncr.25018.

    Article  PubMed  Google Scholar 

  36. Walbert T. Palliative care, end-of-life care, and advance care planning in neuro-oncology. Continuum. 2017;23(6, Neuro-oncology):1709–26. https://doi.org/10.1212/CON.0000000000000538.

    Article  PubMed  Google Scholar 

  37. Struik K, Klein M, Heimans JJ, Gielissen MF, Bleijenberg G, Taphoorn MJ, Reijneveld JC, Postma TJ. Fatigue in low-grade glioma. J Neuro-Oncol. 2009;92(1):73–8. https://doi.org/10.1007/s11060-008-9738-7.

    Article  Google Scholar 

  38. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. NCCN clinical practice guidelines cancer-related fatigue. J Natl Compr Cancer Netw. 2010;8(8):904–31.

    Article  Google Scholar 

  39. Lowe SS, Danielson B, Beaumont C, Watanabe SM, Baracos VE, Courneya KS. Associations between objectively measured physical activity and quality of life in cancer patients with brain metastases. J Pain Symptom Manag. 2014;48(3)

    Article  PubMed  Google Scholar 

  40. Tanay MAL, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care. 2017;26(5) https://doi.org/10.1111/ecc.12443.

    Article  Google Scholar 

  41. Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, for the Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67. https://doi.org/10.1001/jama.2013.2813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67. https://doi.org/10.1200/JCO.2013.54.0914.

    Article  CAS  PubMed  Google Scholar 

  43. Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017;18(12):1600–9. https://doi.org/10.1016/S1470-2045(17)30690-3.

    Article  CAS  PubMed  Google Scholar 

  44. Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A. Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):441–449 e444. https://doi.org/10.1016/j.cllc.2018.05.011.

    Article  CAS  PubMed  Google Scholar 

  45. Ribecco AS, Pino MS, Cipriani G, Marinozzi C, Fioretto L. Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. Expert Rev Anticancer Ther. 2013;13(10):1181–91. https://doi.org/10.1586/14737140.2013.837667.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Funding: Department of Neurosurgery and the Hermelin Brain Tumor Center, Henry Ford Health System.

Conflict of Interest: There are no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Departments of Neurosurgery and Neurology, Henry Ford Health System, Detroit, MI, USA

    Tobias Walbert & Erika S. Horta

Authors
  1. Tobias Walbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erika S. Horta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias Walbert .

Editor information

Editors and Affiliations

  1. Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

    Manmeet Ahluwalia

  2. Department of Neurosurgery and Neuro-Oncology, Clairval Hospital Center, Ramsay-Générale de Santé, Marseille, France, Neurophysiopathology Institute, Aix-Marseille Université, Marseille, France

    Philippe Metellus

  3. Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy

    Riccardo Soffietti

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Walbert, T., Horta, E.S. (2020). Health-Related Quality of Life Related to Toxicity Treatments in Central Nervous System Metastases. In: Ahluwalia, M., Metellus, P., Soffietti, R. (eds) Central Nervous System Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-23417-1_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-23417-1_29

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-23416-4

  • Online ISBN: 978-3-030-23417-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation